Musks $1 trillion pay, a price cut for obesity drugs, Targets in-store woes and more in Morning Squawk

▤ Summary

This newsletter covers several major business and technology headlines, including Tesla shareholder approval of Elon Musk’s massive pay plan. It also highlights ongoing pressure on AI and tech stocks as investors react to valuation concerns and weak market sentiment. In healthcare software and pharma-adjacent technology, the piece notes new U.S. deals with Eli Lilly and Novo Nordisk that could lower obesity drug prices and expand Medicare coverage. The roundup also touches on OpenAI’s revenue ambitions and funding questions, along with Target’s store-operations changes that aim to improve in-store execution.

▦ Linked Companies